4SC
4SC is an innovative biopharmaceutical company based in Planegg-Martinsried near Munich, focusing on drug development in oncology. They develop novel small-molecule drugs for cancer treatment in indications with high medical need and significant economic potential. Their mission is to provide therapies with improved efficacy and tolerability to enhance the quality of life for cancer patients. Their product pipeline includes promising drug programs in various phases of clinical development, driven by fundamental questions in cancer biology to develop innovative cancer medicines.
Industries
Nr. of Employees
medium (51-250)
4SC
Patents
Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy
US-12285410-B2
View Details
Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy
US-12285410-B2
View DetailsProducts
Clinical-stage small-molecule oncology candidate (lead program)
A clinical-stage small-molecule therapeutic program in development for oncology indications with high unmet medical need; managed through clinical studies and regulatory submission processes.
Clinical-stage small-molecule oncology candidate (lead program)
A clinical-stage small-molecule therapeutic program in development for oncology indications with high unmet medical need; managed through clinical studies and regulatory submission processes.
Services
Partnerships and collaboration agreements to co-develop, license or commercialize clinical-stage oncology programs.
Partnerships and collaboration agreements to co-develop, license or commercialize clinical-stage oncology programs.
Expertise Areas
- Oncology drug discovery
- Clinical trial management (oncology)
- Regulatory submissions and EMA interactions
- Commercialization planning for therapeutics
Key Technologies
- Small-molecule therapeutic development
- Clinical trial methodologies and protocol design
- Marketing authorization dossier preparation (MAA)
- Biomarker and cancer biology research methods